GSK director acquires 74 ADS via dividend reinvestment

GSK plc reported a routine insider transaction by non-executive director Dr Hal Barron.

Rhea-AI Filing Summary

GSK plc reported a routine insider transaction by non-executive director Dr Hal Barron. On 2026-05-15, Dr Barron acquired 74 GSK American Depositary Shares at $49.6700 per ADS through dividend reinvestment in his GSK 401(k) plan account on the New York Stock Exchange.

Key Figures

ADS acquired: 74 ADS Purchase price per ADS: $49.6700 per ADS Transaction date: 2026-05-15

3 metrics

ADS acquired 74 ADS Acquisition by Dr Hal Barron via dividend reinvestment

Purchase price per ADS $49.6700 per ADS Dividend reinvestment transaction on NYSE

Transaction date 2026-05-15 Date of insider ADS acquisition

Key Terms

American Depositary Shares, 401(k) plan account, PDMR, LEI

4 terms

American Depositary Shares financial

"Description of the financial instrument | American Depositary Shares ('ADS') ISIN: US37733W2044"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

401(k) plan account financial

"Acquisition of ADS within Dr Barron's GSK 401(k) plan account following the reinvestment of dividends"

PDMR regulatory

"Details of PDMR/person closely associated with them ('PCA')"

A PDMR (person discharging managerial responsibilities) is an individual who can shape a company’s strategy or finances—typically senior executives, board members, or close advisors with decision-making authority. Investors care because PDMRs often hold material, non‑public information and their buying or selling of shares must be reported; monitoring those disclosures is like watching a ship’s captain to read the likely course and spot possible insider risk.

LEI regulatory

"Name | GSK plc b) | LEI | 5493000HZTVUYLO1D793"

A Legal Entity Identifier (LEI) is a unique 20-character code assigned to a company or organization that participates in financial markets, like a corporate passport number. It helps investors and regulators unambiguously identify counterparties across databases and transactions, reducing confusion much like using a vehicle identification number to track a car’s history; clearer identification improves transparency, risk monitoring, and regulatory reporting.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did GSK (GSK) disclose in this Form 6-K?

GSK disclosed that non-executive director Dr Hal Barron acquired 74 American Depositary Shares. The shares were bought at $49.6700 each via dividend reinvestment in his GSK 401(k) plan account.

Who is the GSK (GSK) insider involved in the May 2026 share acquisition?

The insider is Dr Hal Barron, a non-executive director of GSK plc. He acquired shares through his GSK 401(k) plan account via automatic dividend reinvestment rather than an open-market discretionary purchase.

What type of securities did Dr Hal Barron acquire in GSK (GSK)?

Dr Hal Barron acquired American Depositary Shares (ADS) of GSK plc, identified by ISIN US37733W2044. ADS represent an interest in a company’s shares and trade on U.S. exchanges like the New York Stock Exchange.

At what price and volume were GSK (GSK) ADS acquired by Dr Hal Barron?

Dr Hal Barron acquired 74 GSK ADS at a price of $49.6700 per ADS. This single transaction was executed on the New York Stock Exchange and reported as aggregated information not being applicable.

When and where was the GSK (GSK) insider transaction executed?

The transaction occurred on 2026-05-15 on the New York Stock Exchange (XNYS). The Form 6-K notes this as a transaction involving dividend reinvestment in Dr Barron’s GSK 401(k) plan account.

What was the nature of Dr Hal Barron’s GSK (GSK) share acquisition?

The filing describes the transaction as an acquisition of ADS within Dr Barron’s GSK 401(k) plan account. The shares were obtained through the reinvestment of dividends, indicating an automatic plan mechanism rather than a separate market order.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/20/2026 - 10:40 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of May 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

GSK plc (the 'Company')

Transaction notification

​

1.	Details of PDMR/person closely associated with them ('PCA')
a)	Name	Dr Hal Barron
b)	Position/status	Non-Executive Director
c)	Initial notification/amendment	Initial notification
2.	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	GSK plc
b)	LEI	5493000HZTVUYLO1D793
3.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)	Description of the financial instrument	American Depositary Shares ('ADS') ISIN: US37733W2044
b)	Nature of the transaction	Acquisition of ADS within Dr Barron's GSK 401(k) plan account following the reinvestment of dividends
c)	Price(s) and volume(s)		Price(s)	Volume(s)
			$49.6700	74
		d)	Aggregated information	N/A (single transaction)
Aggregated volume Price
e)	Date of the transaction	2026-05-15
f)	Place of the transaction	New York Stock Exchange (XNYS)

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: May 20, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc